Cytogeneticists are increasingly adopting chromosomal microarrays for prenatal diagnostics, but have not yet reached a consensus when it comes to what kinds of cases should undergo array-based screening and which platform is best to use.

In addition, findings of unknown clinical significance continue to slow the uptake of the technology for prenatal testing, as some in the cytogenetics community hope that time, and experience, will put to rest most of the questions about the new technology and the data it provides.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.